RT Journal Article
SR Electronic
T1 DGI-031 Efficacy of Oral Thalidomide in Patients with Recurrent Gastrointestinal Bleeding
JF European Journal of Hospital Pharmacy: Science and Practice
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP A106
OP A106
DO 10.1136/ejhpharm-2013-000276.297
VO 20
IS Suppl 1
A1 Fernandez, C García
A1 Fuentes, S Ruiz
A1 Peña, C Gómez
A1 Rustarazo, S Belda
A1 López, C Fernandez
A1 Caballero, C Medarde
A1 Martinez, D Blanquez
A1 Romero, A Caballero
YR 2013
UL http://ejhp.bmj.com/content/20/Suppl_1/A106.3.abstract
AB Background Recurrent gastrointestinal bleeding caused by angiodysplasia, and not responding to standard treatment, currently lacks effective medical treatment. Purpose To evaluate the efficacy of oral thalidomide in patients with gastrointestinal bleeding from angiodysplasia refractory to other treatments. Materials and Methods Retrospective study for a year including all patients with recurrent gastrointestinal bleeding treated with oral thalidomide manufactured in the pharmacotechnic unit of a tertiary level hospital. The information was obtained from the outpatient dispensing programme Farmatools, the Paracelso pharmacotechnics programme, and by reviewing medical records from the hospital 1, Archinet. For each patient we extracted the diagnosis, treatments used for gastrointestinal bleeding, line and duration of treatment with thalidomide and transfusion requirements after treatment. Results In the study period were identified 3 patients for whom the Digestive Service ordered thalidomide capsules 100 mg. The patients had not responded to standard treatments such as argon gas sessions and octreotide. They were introduced to thalidomide 100 mg daily for 4 months. One of them discontinued treatment for intolerance and the other 2 completed the course. There was a decrease in the number of transfusions after treatment with thalidomide in all 3 cases. Conclusions Thalidomide appears to be a therapeutic alternative to consider when treating gastrointestinal bleeding caused by angiodysplasia in cases where there is no response to conventional treatments. One impediment to this treatment option is intolerance in some patients, leading to treatment discontinuation. Thalidomide is less aggressive than other drugs used and appears to decrease patients’ transfusion requirements. No conflict of interest.